NCT03959332View on ClinicalTrials.gov

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

July 11, 2019

Study Completion Date

July 11, 2019

Conditions
Healthy Volunteer
Interventions
DRUG

Baloxavir Marboxil

Participants will receive either 40 mg or 80 mg of baloxavir marboxil on Day 1 as a single oral dose.

Trial Locations (1)

200031

Shanghai Xuhui Central Hospital, Shanghai

Sponsors

Collaborators (1)

Shionogi
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY